^{Sources: Forbes}

Pfizer Inc. (NYSE: PFE) has announced the discontinuation of its once-daily oral weight-loss drug, danuglipron, following a potential drug-induced liver injury observed in a clinical trial participant. This decision marks a significant shift in the company's approach to the burgeoning obesity treatment market.​

Clinical Trial Setback

The decision to halt development comes after a patient in the trial experienced a liver injury potentially linked to danuglipron. Although the injury resolved after discontinuation of the drug, Pfizer opted to cease further development after evaluating all clinical data and receiving regulatory feedback .​

This is the third setback for Pfizer in its pursuit of an effective oral obesity treatment. Previously, the company discontinued a twice-daily version of danuglipron in 2023 due to high dropout rates from side effects like nausea and vomiting. Another candidate, lotiglipron, was also abandoned over similar safety concerns .​‍

Market Implications

The global obesity treatment market is projected to reach $150 billion, with significant interest in oral medications due to the inconvenience of injectable options. Pfizer's withdrawal from danuglipron development may impact its position in this lucrative market, currently dominated by injectable drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound .​‍

Despite this setback, Pfizer's stock experienced a slight decline of over 1% in premarket trading. The company remains committed to obesity research and is focusing on other drug candidates, including PF-07976016, a daily pill targeting the GIP receptor, currently in Phase 2 trials .​

Future Outlook

Pfizer's Chief Scientific Officer, Dr. Chris Boshoff, stated, "While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients" .​

The company plans to present the clinical data of danuglipron at upcoming scientific forums or in peer-reviewed journals, contributing to the broader scientific understanding of obesity treatments.​

‍